US Trade Representative retains India on priority watch list on IPR; Vietnam faces toughest scrutiny

The United States Trade Representative (USTR) released its annual Special 301 Report on April 30, 2026, retaining India on the Priority Watch List for intell...

What Happened

The United States Trade Representative (USTR) released its annual Special 301 Report on April 30, 2026, retaining India on the Priority Watch List for intellectual property rights (IPR) concerns.
India is one of six countries on the Priority Watch List alongside Chile, China, Indonesia, Russia, and Venezuela.
The 2026 report flags concerns including pharmaceutical patent practices, medical device price controls, and enforcement gaps against piracy and counterfeiting.
Vietnam received the most serious designation — Priority Foreign Country (PFC) — marking the first such designation in 13 years; the USTR will decide within 30 days whether to initiate a Section 301 investigation against Vietnam.
Argentina and Mexico were upgraded to the less serious Watch List after showing IP policy improvements; the European Union was newly added to the Watch List.
The Special 301 process is a unilateral US review mechanism; it does not impose immediate penalties but can escalate to trade investigations and retaliatory measures.

Static Topic Bridges

The Special 301 Report: What It Is and Why It Matters

The Special 301 Report is an annual review published by the USTR under Section 182 of the Trade Act of 1974 (as amended by the Omnibus Trade and Competitiveness Act of 1988). It assesses intellectual property protection and enforcement practices among US trading partners. Countries are placed in one of three tiers: Watch List, Priority Watch List, or Priority Foreign Country. Being on the Priority Watch List signals that a country has "particular problems" requiring intensive US bilateral engagement. It is a diplomatic and trade pressure tool, not a legally binding judgment, but a Priority Foreign Country designation can trigger a formal investigation under Section 301, which may eventually lead to tariff retaliation.

Published annually, typically in April-May.
Over 100 trading partners reviewed each cycle.
Priority Foreign Country is the most serious tier; no immediate trade action flows automatically from Priority Watch List placement.
The Report relies on submissions from US industry groups, foreign governments, and other stakeholders.

Connection to this news: India has remained on the Priority Watch List since the 1990s, making this a recurring bilateral irritant. Each annual report keeps diplomatic pressure on India to modify its IP regime, particularly in pharmaceuticals and digital trade.

India's Pharmaceutical Patent Framework and TRIPS Flexibilities

India's patent law, rooted in the Patents Act 1970 (as amended in 2005), incorporates several flexibilities permitted under the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The most cited provision is Section 3(d), which bars patents on new forms of known substances (such as salts, polymorphs, or esters of existing drugs) unless the applicant proves significantly enhanced therapeutic efficacy. This prevents the practice of "evergreening" — minor modifications to extend monopoly protection without adding meaningful medical benefit.

India became compliant with the full TRIPS product patent regime in January 2005.
Section 84 of the Patents Act allows compulsory licensing if a patented product is unavailable at a reasonably affordable price, is not adequately worked in India, or fails to meet public requirements.
India's first compulsory licence was granted in 2012 (Natco Pharma vs. Bayer Corporation) for the cancer drug Sorafenib Tosylate; the generic price fell from approximately ₹2.8 lakh to ₹8,800 per month.
The 2001 Doha Declaration on TRIPS and Public Health reaffirmed that countries may use TRIPS flexibilities to protect public health.
India supplies approximately 20% of the world's generic medicines; generics typically cost 80–90% less than branded originals.

Connection to this news: The USTR specifically criticises Section 3(d) and India's compulsory licensing provisions as falling short of TRIPS-plus standards (such as data exclusivity) sought by US pharmaceutical industry groups. India considers its framework fully WTO-compliant and consistent with public health obligations.

National Pharmaceutical Pricing Authority (NPPA) and Medical Device Price Controls

The NPPA, established under the Drugs (Prices Control) Order, regulates prices of essential medicines and medical devices in India. In recent years, price caps were extended to coronary stents (2017) and knee implants (2017), reducing patient costs significantly but drawing criticism from multinational manufacturers who argue the controls suppress innovation incentives.

NPPA operates under the Ministry of Chemicals and Fertilizers.
The Drug Price Control Order (DPCO) 2013 provides the legal framework for essential medicine pricing.
Stent prices were capped in 2017; bare-metal stents and drug-eluting stents saw prices cut by up to 85%.
The USTR 2026 report identifies India's medical device price controls as a market-access concern alongside pharmaceutical patents.

Connection to this news: The USTR report flags price caps on stents and knee implants as barriers that reduce returns on IP-intensive medical technology investment — a newer front in the US-India IP dispute beyond the traditional pharmaceutical patent debate.

Key Facts & Data

Countries on 2026 Priority Watch List: Chile, China, India, Indonesia, Russia, Venezuela (6 total).
2026 Priority Foreign Country: Vietnam (first such designation in 13 years).
Countries on Watch List (19): includes Algeria, Argentina, Brazil, Canada, the European Union, Mexico, Pakistan, and others.
Total trading partners reviewed: over 100.
India has been on the Priority Watch List continuously since the 1990s.
India amended its patent rules in 2024 to improve procedural efficiency.
Section 84 of the Patents Act governs compulsory licensing; Section 3(d) governs patentability standards for new forms of known substances.
The Special 301 Report is issued under Section 182 of the US Trade Act of 1974.